These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 9280964

  • 1. [Pravastatin increases the activity pf the LDL receptors in lymphocytes of individuals with heterozygous familial hypercholesterolemia].
    Alvarez-Sala LA, Mata P, Blázquez E, Garrido JA, Ordovás JM, Rubio MJ, de Oya M.
    Rev Clin Esp; 1997 May; 197(5):317-22. PubMed ID: 9280964
    [Abstract] [Full Text] [Related]

  • 2. Plasma lipoprotein changes after treatment with pravastatin and gemfibrozil in patients with familial hypercholesterolemia.
    Franceschini G, Sirtori M, Vaccarino V, Gianfranceschi G, Chiesa G, Sirtori CR.
    J Lab Clin Med; 1989 Sep; 114(3):250-9. PubMed ID: 2504855
    [Abstract] [Full Text] [Related]

  • 3. Atherogenic lipoprotein particle size and concentrations and the effect of pravastatin in children with familial hypercholesterolemia.
    van der Graaf A, Rodenburg J, Vissers MN, Hutten BA, Wiegman A, Trip MD, Stroes ES, Wijburg FA, Otvos JD, Kastelein JJ.
    J Pediatr; 2008 Jun; 152(6):873-8. PubMed ID: 18492534
    [Abstract] [Full Text] [Related]

  • 4. Oxidized low-density lipoprotein in children with familial hypercholesterolemia and unaffected siblings: effect of pravastatin.
    Rodenburg J, Vissers MN, Wiegman A, Miller ER, Ridker PM, Witztum JL, Kastelein JJ, Tsimikas S.
    J Am Coll Cardiol; 2006 May 02; 47(9):1803-10. PubMed ID: 16682304
    [Abstract] [Full Text] [Related]

  • 5. Effects of pravastatin on lipid transfer protein and lecithin cholesterol acyltransferase in heterozygous familial hypercholesterolemia.
    Fusegawa Y, Tada H, Oguma T, Shiina Y, Moriguchi EH, Tanabe T, Tamachi H, Tomoda H, Goto Y.
    Tokai J Exp Clin Med; 1993 Dec 02; 18(3-6):81-6. PubMed ID: 7701533
    [Abstract] [Full Text] [Related]

  • 6. Effect of pravastatin, an HMG CoA reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by their apolipoprotein composition.
    Bard JM, Parra HJ, Douste-Blazy P, Fruchart JC.
    Metabolism; 1990 Mar 02; 39(3):269-73. PubMed ID: 2106607
    [Abstract] [Full Text] [Related]

  • 7. [Comparison of the effectiveness of the HMG-CoA-reductase inhibitors pravastatin versus colestyramine in hypercholesteremia].
    Schwartzkopff W, Bimmermann A, Schleicher J.
    Arzneimittelforschung; 1990 Dec 02; 40(12):1322-7. PubMed ID: 2128866
    [Abstract] [Full Text] [Related]

  • 8. Accumulation of "small dense" low density lipoproteins (LDL) in a homozygous patients with familial defective apolipoprotein B-100 results from heterogenous interaction of LDL subfractions with the LDL receptor.
    März W, Baumstark MW, Scharnagl H, Ruzicka V, Buxbaum S, Herwig J, Pohl T, Russ A, Schaaf L, Berg A.
    J Clin Invest; 1993 Dec 02; 92(6):2922-33. PubMed ID: 8254047
    [Abstract] [Full Text] [Related]

  • 9. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
    Jones PH, Hunninghake DB, Ferdinand KC, Stein EA, Gold A, Caplan RJ, Blasetto JW, Statin Therapies for Elevated Lipid Levels Compared Across Doses to Rosuvastatin Study Group.
    Clin Ther; 2004 Sep 02; 26(9):1388-99. PubMed ID: 15531001
    [Abstract] [Full Text] [Related]

  • 10. One-year atorvastatin treatment in hypercholesterolemic patients with or without carotid artery disease.
    Avellone G, Di Garbo V, Abruzzese G, Campisi D, De Simone R, Raneli G, Licata G.
    Int Angiol; 2006 Mar 02; 25(1):26-34. PubMed ID: 16520721
    [Abstract] [Full Text] [Related]

  • 11. Assessment of functional low-density lipoprotein receptor activity on lymphocytes of normal subjects and patients with familial hypercholesterolemia.
    Cuthbert JA, Lipsky PE.
    Trans Assoc Am Physicians; 1988 Mar 02; 101():1-11. PubMed ID: 3269672
    [Abstract] [Full Text] [Related]

  • 12. Effect of simvastatin in familial hypercholesterolemia on the affinity of electronegative low-density lipoprotein subfractions to the low-density lipoprotein receptor.
    Benítez S, Ordóñez-Llanos J, Franco M, Marín C, Paz E, López-Miranda J, Otal C, Pérez-Jiménez F, Sánchez-Quesada JL.
    Am J Cardiol; 2004 Feb 15; 93(4):414-20. PubMed ID: 14969613
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics and pharmacodynamics of pravastatin in children with familial hypercholesterolemia.
    Hedman M, Neuvonen PJ, Neuvonen M, Antikainen M.
    Clin Pharmacol Ther; 2003 Aug 15; 74(2):178-85. PubMed ID: 12891228
    [Abstract] [Full Text] [Related]

  • 14. Differing effects of low-dose estrogen-progestin therapy and pravastatin in postmenopausal hypercholesterolemic women.
    Davis SR, Goldstat R, Newman A, Berry K, Burger HG, Meredith I, Koch K.
    Climacteric; 2002 Dec 15; 5(4):341-50. PubMed ID: 12626213
    [Abstract] [Full Text] [Related]

  • 15. Effects of policosanol and pravastatin on lipid profile, platelet aggregation and endothelemia in older hypercholesterolemic patients.
    Castaño G, Más R, Arruzazabala ML, Noa M, Illnait J, Fernández JC, Molina V, Menéndez A.
    Int J Clin Pharmacol Res; 1999 Dec 15; 19(4):105-16. PubMed ID: 10939028
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effects of CS-514 (eptastatin), an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, on serum lipid and apolipoprotein levels in heterozygous familial hypercholesterolemic patients treated by low density lipoprotein (LDL)-apheresis.
    Mabuchi H, Fujita H, Michishita I, Takeda M, Kajinami K, Koizumi J, Takeda R, Takegoshi T, Wakasugi T, Ueda K.
    Atherosclerosis; 1988 Aug 15; 72(2-3):183-8. PubMed ID: 3145745
    [Abstract] [Full Text] [Related]

  • 19. Baseline levels of low-density lipoprotein cholesterol and lipoprotein (a) and the AvaII polymorphism of the low-density lipoprotein receptor gene influence the response of low-density lipoprotein cholesterol to pravastatin treatment.
    Lahoz C, Peña R, Mostaza JM, Laguna F, García-Iglesias MF, Taboada M, Pintó X.
    Metabolism; 2005 Jun 15; 54(6):741-7. PubMed ID: 15931608
    [Abstract] [Full Text] [Related]

  • 20. Familial defective apolipoprotein B-100.
    Hansen PS.
    Dan Med Bull; 1998 Sep 15; 45(4):370-82. PubMed ID: 9777289
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.